Abstract
Whereas most SGA children experience spontaneous catch-up growth leading to the achievement of normal adult height, approximately 10% remain short and are candidates for GH therapy. SGA subjects have increased cardio-metabolic disease risk [17] and the effects of GH treatment on blood pressure, body composition, glucose metabolism and lipid profile have been investigated [18]. Recently, interest has been focused on the cardiovascular disease risk in adults treated with GH during childhood. Data from the French SAGhE (Safety and Appropriateness of GH therapy in Europe) study cohort have shown increased cerebrovascular mortality rate [19], although not confirmed in other SAGhE cohorts [20]. In theory, children born SGA, having intrinsic higher cardio-metabolic risk, might be at even higher risk if exposed to long-term GH therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
